P04.4
⚠ Non-billable (Header)Newborn affected by maternal use of drugs of addiction
Certain conditions originating in the perinatal period (P00-P96)
⚠️ This is a category header code — not billable. Use a more specific child code below.
⚠️ Excludes2
inheritedRules inherited from parent codes.
- • congenital malformations (Q00-Q99)
- • encounter for observation of newborn for suspected diseases and conditions ruled out (Z05.-)
- • neonatal jaundice from excessive hemolysis due to drugs or toxins transmitted from mother (P58.4)
- • newborn in contact with and (suspected) exposures hazardous to health not transmitted via placenta or breast milk (Z77.-)
📋 Code Instructions
inherited- • Code first: any current condition in newborn, if applicable
Child Codes (4)
Clinical Description
ICD-10-CM code P04.4 represents newborn affected by maternal use of drugs of addiction. This code falls under the Certain conditions originating in the perinatal period (P00-P96) classification. It is a non-billable category header code. A more specific child code from the list below must be used for billing and reimbursement purposes.
This is a 5-character code at the 4th level of specificity. There are 4 more specific child codes under P04.4.
Frequently Asked Questions
What is ICD-10 code P04.4?
ICD-10-CM code P04.4 is "Newborn affected by maternal use of drugs of addiction". It belongs to the category: Certain conditions originating in the perinatal period (P00-P96).
Is P04.4 a billable ICD-10 code?
No, P04.4 is a non-billable header code. A more specific child code must be used for billing.
Can P04.4 be coded with other codes?
P04.4 has 4 Excludes2 note(s). These conditions can be coded together if both are documented in the patient record.
Related Codes in P04
Other codes in the same category that may be relevant for differential coding:
🧪 Validate Combinations
Add P04.4 to the Excludes Checker to validate against your full code list.
Open in Checker →Code Information
Data Source
CMS ICD-10-CM 2026 Tabular List
Updated October 1, 2025 (FY2026)